- Home
- LIXT vs SBFM Comparison
LIXT vs SBFM Comparison
Compare LIXT & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- SBFM
- Stock Information
- Founded
- LIXT 2005
- SBFM 2006
- Country
- LIXT United States
- SBFM United States
- Employees
- LIXT N/A
- SBFM N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- LIXT Health Care
- SBFM Health Care
- Exchange
- LIXT Nasdaq
- SBFM Nasdaq
- Market Cap
- LIXT 4.1M
- SBFM 3.7M
- IPO Year
- LIXT N/A
- SBFM N/A
- Fundamental
- Price
- LIXT $1.93
- SBFM $2.78
- Analyst Decision
- LIXT
- SBFM Strong Buy
- Analyst Count
- LIXT 0
- SBFM 1
- Target Price
- LIXT N/A
- SBFM $15.00
- AVG Volume (30 Days)
- LIXT 19.4K
- SBFM 1.8M
- Earning Date
- LIXT 11-12-2024
- SBFM 11-05-2024
- Dividend Yield
- LIXT N/A
- SBFM N/A
- EPS Growth
- LIXT N/A
- SBFM N/A
- EPS
- LIXT N/A
- SBFM N/A
- Revenue
- LIXT N/A
- SBFM $32,959,491.00
- Revenue This Year
- LIXT N/A
- SBFM $86.70
- Revenue Next Year
- LIXT N/A
- SBFM $126.76
- P/E Ratio
- LIXT N/A
- SBFM N/A
- Revenue Growth
- LIXT N/A
- SBFM 61.94
- 52 Week Low
- LIXT $1.31
- SBFM $2.11
- 52 Week High
- LIXT $4.40
- SBFM $608.00
- Technical
- Relative Strength Index (RSI)
- LIXT 57.92
- SBFM 47.83
- Support Level
- LIXT $1.85
- SBFM $2.51
- Resistance Level
- LIXT $2.65
- SBFM $2.82
- Average True Range (ATR)
- LIXT 0.18
- SBFM 0.29
- MACD
- LIXT 0.03
- SBFM -0.02
- Stochastic Oscillator
- LIXT 43.37
- SBFM 22.34
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.